Effect of perioperative venous thromboembolism on survival in ovarian, primary peritoneal, and fallopian tube cancer

Gynecologic Oncology

Volumn 107, Issue 1, 2007, Pages 66-70

  Black, Destin ^a   Iasonos, Alexia ^a   Ahmed, Hina ^a   Chi, Dennis S ^a   Barakat, Richard R ^a   Abu Rustum, Nadeem R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Fallopian tube cancer; Ovarian cancer; Primary peritoneal cancer; Survival; Venous thromboembolism

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER STAGING; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MINIMAL RESIDUAL DISEASE; MULTIVARIATE ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PERITONEUM CANCER; PREDICTOR VARIABLE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; UTERINE TUBE CARCINOMA; VENOUS THROMBOEMBOLISM;

ADULT; AGED; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM, RESIDUAL; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; SURVIVAL RATE; VENOUS THROMBOSIS;

EID: 34648835209     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.05.040     Document Type: Article

References (23)

1. Trousseau A., Bazire V., and Cormack J.R. Lectures on clinical medicine, delivered at the Hotel-Dieu, Paris (1867), R. Hardwicke, London
2. Khorana A.A. Malignancy, thrombosis and Trousseau: the case for an eponym. J. Thromb. Haemost. 1 (2003) 2463-2465
3. Rak J., Yu J.L., Luyendyk J., and Mackman N. Oncogenes, trousseau syndrome, and cancer-related changes in the coagulome of mice and humans. Cancer Res. 66 (2006) 10643-10646
4. Lugassy G, Thrombosis and cancer. London; New York Boca Raton, FL: Martin Dunitz; Distributed in North America by Taylor and Francis; 2004.
5. Gale A.J., and Gordon S.G. Update on tumor cell procoagulant factors. Acta Haematol. 106 (2001) 25-32
6. Sampson M.T., and Kakkar A.K. Coagulation proteases and human cancer. Biochem. Soc. Trans. 30 (2002) 201-207
7. Wang X., Wang E., Kavanagh J.J., and Freedman R.S. Ovarian cancer, the coagulation pathway, and inflammation. J. Transl. Med. 3 (2005) 25
8. von Tempelhoff G.F., Nieman F., Heilmann L., and Hommel G. Association between blood rheology, thrombosis and cancer survival in patients with gynecologic malignancy. Clin. Hemorheol. Microcirc. 22 (2000) 107-130
9. Gadducci A., Baicchi U., Marrai R., Del Bravo B., Fosella P.V., and Facchini V. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma. Gynecol. Oncol. 53 (1994) 352-356
10. Koh S.C., Tham K.F., Razvi K., Oei P.L., Lim F.K., Roy A.C., et al. Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?. Clin. Appl. Thromb. Hemost. 7 (2001) 141-148
11. Collett D. Modelling survival data in medical research. 2nd ed. (2003), Chapman and Hall/CRC, Boca Raton, Fla
12. Abu-Rustum N.R., Richard S., Wilton A., Lev G., Sonoda Y., Hensley M.L., et al. Transfusion utilization during adnexal or peritoneal cancer surgery: effects on symptomatic venous thromboembolism and survival. Gynecol. Oncol. 99 (2005) 320-326
13. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol. Oncol. 94 (2004) 650-654
14. Chew H.K., Wun T., Harvey D., Zhou H., and White R.H. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166 (2006) 458-464
15. Lee A.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 (2003) I17-I21
16. Sorensen H.T., Mellemkjaer L., Olsen J.H., and Baron J.A. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343 (2000) 1846-1850
17. Alcalay A., Wun T., Khatri V., Chew H.K., Harvey D., Zhou H., et al. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J. Clin. Oncol. 24 (2006) 1112-1118
18. Chew H.K., Wun T., Harvey D.J., Zhou H., and White R.H. Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J. Clin. Oncol. 25 (2007) 70-76
19. Tetsche M.S., Norgaard M., Pedersen L., Lash T.L., and Sorensen H.T. Prognosis of ovarian cancer subsequent to venous thromboembolism: a nationwide Danish cohort study. BMC Cancer 6 (2006) 189
20. Tateo S., Mereu L., Salamano S., Klersy C., Barone M., Spyropoulos A.C., P., et al. Ovarian cancer and venous thromboembolic risk. Gynecol. Oncol. 99 (2005) 119-125
21. Klerk C.P., Smorenburg S.M., Otten H.M., Lensing A.W., Prins M.H., Piovella F., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. 23 (2005) 2130-2135
22. Kakkar A.K., Levine M.N., Kadziola Z., Lemoine N.R., Low V., Patel H.K., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J. Clin. Oncol. 22 (2004) 1944-1948
23. Lee A.Y., Rickles F.R., Julian J.A., Gent M., Baker R.I., Bowden C., et al. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J. Clin. Oncol. 23 (2005) 2123-2129